Inotiv ranked 182nd on Deloitte's Technology Fast 500™, with a 448% revenue growth from 2021 to 2024.
Quiver AI Summary
Inotiv has been recognized as the 182nd fastest-growing company in North America according to the Deloitte Technology Fast 500™, which ranks high-growth organizations in various sectors. The company achieved an impressive revenue growth of 448% from fiscal year 2021 to fiscal year 2024, marking its third consecutive year on the list. President and CEO Robert Leasure, Jr. attributes this success to the company’s commitment to client partnerships and strategic growth, highlighting the importance of listening to customer needs and refining service delivery. The rankings showcase both established leaders and new innovators, revealing a trend of significant growth in the private sector. Inotiv continues to focus on providing essential research services to enhance drug discovery and development, affirming its dedication to advancing health solutions.
Potential Positives
- Inotiv ranked 182nd on the Deloitte Technology Fast 500™, highlighting its significant growth and recognition among leading technology companies in North America.
- Revenue growth of 448% from fiscal year 2021 to fiscal year 2024 underscores Inotiv's strong financial performance and market potential.
- This marks Inotiv's third consecutive year being recognized in the Deloitte Technology Fast 500™, solidifying its position as a leading player in its industry.
Potential Negatives
- Inotiv's ranking dropped from 127th to 182nd in the Deloitte Technology Fast 500™, indicating a decline in its growth rate compared to previous years.
- The company experienced significant revenue growth (448%) but still ranked lower, which could raise questions about the sustainability of this growth moving forward.
- Being recognized as a slower-growing company in a fast-paced industry may negatively impact investor confidence and perceptions of Inotiv's competitive position.
FAQ
What is the Deloitte Technology Fast 500™ ranking?
The Deloitte Technology Fast 500™ ranks the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America.
What was Inotiv's revenue growth between 2021 and 2024?
Inotiv's revenue grew 448% from fiscal year 2021 to fiscal year 2024, marking significant growth in that period.
How many years has Inotiv been recognized in the Fast 500 rankings?
Inotiv has been recognized in the Deloitte Technology Fast 500™ rankings for three consecutive years: 2023, 2024, and 2025.
Who is the CEO of Inotiv?
Robert Leasure, Jr. is the President and Chief Executive Officer of Inotiv, leading the company through its growth.
What services does Inotiv specialize in?
Inotiv specializes in nonclinical and analytical drug discovery and development services, focusing on aiding researchers in bringing new drugs and medical devices to market.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$NOTV Insider Trading Activity
$NOTV insiders have traded $NOTV stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $NOTV stock by insiders over the last 6 months:
- R MATTHEW NEFF has made 0 purchases and 6 sales selling 12,000 shares for an estimated $21,367.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$NOTV Hedge Fund Activity
We have seen 32 institutional investors add shares of $NOTV stock to their portfolio, and 42 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- KENNEDY CAPITAL MANAGEMENT LLC removed 1,003,801 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $1,826,917
- BALYASNY ASSET MANAGEMENT L.P. removed 668,912 shares (-40.4%) from their portfolio in Q3 2025, for an estimated $969,922
- MILLENNIUM MANAGEMENT LLC removed 276,705 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $401,222
- GSA CAPITAL PARTNERS LLP added 234,518 shares (+inf%) to their portfolio in Q3 2025, for an estimated $340,051
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 234,120 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $339,474
- THURSTON, SPRINGER, MILLER, HERD & TITAK, INC. removed 177,725 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $257,701
- EHP FUNDS INC. added 148,521 shares (+inf%) to their portfolio in Q3 2025, for an estimated $215,355
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
WEST LAFAYETTE, Ind., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Inotiv today announced it ranked 182 nd on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 31st year. Inotiv’s revenue grew 448% from fiscal year 2021 to fiscal year 2024, the measurement period for this year’s rankings.
Robert Leasure, Jr., President and Chief Executive Officer of Inotiv credits the company’s ongoing success to its focus on clients, scientific partnership, and strategic growth. He said, "We are honored to be recognized as a Deloitte Technology Fast 500™ winner for the third consecutive year, a reflection of the trust our clients place in us and the dedication of our teams across the organization. Over the past several years, we’ve come together as one Inotiv, building our company through strategic acquisitions and the development of complementary services that enhance our ability to support our clients’ critical research. By listening closely to our customers and continually refining how we deliver our solutions and research models, we’re creating a client experience rooted in partnership, scientific excellence and reliability. As we evolve, our commitment remains clear: to be a trusted partner helping our clients advance life-changing therapies.”
“This year’s rankings highlight both enduring leadership and breakthrough momentum,” said Wolfe Tone, US Deloitte Private & Emerging Client Portfolio leader and partner, Deloitte Tax LLP. “More than half of the winners are prior honorees, yet the majority of the top ten are first-time entrants — demonstrating the staying power of established leaders alongside the accelerating growth of new innovators across key sectors. As in previous years, private companies continue to dominate, underscoring the agility that private enterprises bring to competitive markets, enabling the exceptional triple and quadruple digit growth reflected in these rankings.”
Inotiv was previously ranked 138 th and 127 th as a Technology Fast 500™ award winner for 2024 and 2023, respectively.
About the 2025 Deloitte Technology Fast 500
Now in its 31st year, the Deloitte Technology Fast 500 provides a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies — both public and private — in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from fiscal year 2021 to fiscal year 2024.
In order to be eligible for the Deloitte Technology Fast 500 recognition, companies must own proprietary intellectual property or proprietary technology that significantly contributes to the company’s operating revenues. Companies must have base-year operating revenues of at least US$50,000, and current-year operating revenues of at least US$5 million, with a growth rate of 50% or greater. Additionally, companies must be in business for a minimum of four years and be headquartered within North America (United States and Canada).
About Inotiv
Inotiv, Inc. is a leading contract research organization dedicated to providing nonclinical and analytical drug discovery and development services and research models and related products and services. The Company’s products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development, all while increasing efficiency, improving data, and reducing the cost of taking new drugs and medical devices to market. Inotiv is committed to supporting discovery and development objectives as well as helping researchers realize the full potential of their critical research and development projects, all while working together to build a healthier and safer world. Further information about Inotiv can be found here:
https://www.inotiv.com/
.
|
Company Contact
|
Investor Relations |
| Inotiv, Inc. | LifeSci Advisors |
| Beth A. Taylor, Chief Financial Officer | Steve Halper |
| (765) 497-8381 | (646) 876-6455 |
| be th. [email protected] | [email protected] |
*Please see www.deloitte.com/us/about for a detailed description of their legal structure.